SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer

Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer
EN
05/10/2020

Underlying

SUPNSupernus Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Supernus Pharmaceuticals Inc.

 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus Announces Record Fourth Quarter and Full Year 2025 Financial ...

Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively. The strong growth in both periods was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO...

February 24, 2026 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus Pharmaceuticals to Participate in March Investor Conferences

Supernus Pharmaceuticals to Participate in March Investor Conferences ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following March investor conferences: TD Cowen 46th Annual Health Care ConferenceDate:Fireside chat:Place:Webcast Link:Monday, March 2, 20262:30 p.m. ETBoston Marriott Copley Place, Boston, Mass.Jefferies Biotech on the Beach SummitD...

February 23, 2026 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025...

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026 ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026. Jack Khattar, President and CEO, and Tim Dec, Senior...

February 12, 2026 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus Pharmaceuticals to Participate in the Bank of America Securit...

Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on Monday, December 8, 2025, at 3:20 p.m. ET. Investors interested in ...

December 3, 2025 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annu...

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 4:00 p.m. ET at the Lotte New York Palace in New York C...

November 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch